NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions announced that its board has approved a stock buyback program on Friday, March 23rd 2018, which authorizes the company to repurchase $50,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

Emergent Biosolutions Inc (NYSE:EBS) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.58. The biopharmaceutical company earned $311.80 million during the quarter, compared to analysts' expectations of $289.16 million. Emergent Biosolutions had a net margin of 0.42% and a return on equity of 10.05%. The company's quarterly revenue was up 79.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.55 EPS. View Emergent Biosolutions' Earnings History.

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Emergent Biosolutions.

Emergent Biosolutions issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.1-1.105 billion, compared to the consensus revenue estimate of $1.11 billion.

6 Wall Street analysts have issued 12-month target prices for Emergent Biosolutions' stock. Their forecasts range from $64.00 to $75.00. On average, they anticipate Emergent Biosolutions' stock price to reach $69.00 in the next year. This suggests a possible upside of 22.9% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.

News coverage about EBS stock has trended somewhat negative this week, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Emergent Biosolutions earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Emergent Biosolutions.

Emergent Biosolutions saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,450,000 shares, an increase of 12.4% from the December 15th total of 2,180,000 shares. Based on an average daily trading volume, of 303,800 shares, the days-to-cover ratio is currently 8.1 days. Approximately 5.7% of the shares of the stock are sold short. View Emergent Biosolutions' Current Options Chain.

Some companies that are related to Emergent Biosolutions include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Netflix (NFLX), NVIDIA (NVDA), NXP Semiconductors (NXPI), CalAmp (CAMP), Gentherm (THRM), AbbVie (ABBV) and Gilead Sciences (GILD).

Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.58%), Strs Ohio (0.15%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.06%), Louisiana State Employees Retirement System (0.03%) and First Hawaiian Bank (0.02%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

EBS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Nisa Investment Advisors LLC, Louisiana State Employees Retirement System, First Hawaiian Bank and State of Alaska Department of Revenue. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon, Sue Bailey and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

EBS stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Honkamp Krueger Financial Services Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Emergent Biosolutions.

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EBS stock can currently be purchased for approximately $56.15.

Emergent Biosolutions has a market capitalization of $2.90 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/.

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]